Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Inizio celebrates six finalist honors at the 2025 PM360 Trailblazer Awards

September 24, 2025 |  

Inizio has been named a finalist in six categories at the 2025 PM360 Trailblazer Awards, recognizing its teams’ excellence in AI, data analytics, education, patient engagement, and industry partnership across Inizio Evoke, Inizio Engage, and Inizio Medical.

PM360AwardsInizio

We’re proud to announce that our teams across Inizio Evoke, Inizio Engage, and Inizio Medical have been named finalists in six prestigious categories at the 2025 PM360 Trailblazer Awards, which recognize excellence and innovation in healthcare marketing. 

The PM360 Trailblazer Awards honor the most impactful initiatives, strategies, and companies driving change in the healthcare industry across eight core categories. This year, our recognition spans multiple disciplines – highlighting our expertise in artificial intelligence (AI), data analytics, patient and healthcare professional (HCP) education, and persistence/adherence programs, as well as our standing as a top industry partner. 

Our 2025 PM360 trailblazer award finalist categories 

Driving innovation across healthcare marketing 

These finalist recognitions demonstrate how our connected capabilities empower life sciences organizations to achieve greater patient engagement, educational impact, and data-driven decision-making. Our work leverages cutting-edge AI and analytics, compelling creative strategies, and deep scientific expertise to deliver measurable results for our clients and ultimately improve healthcare outcomes. 

Looking ahead 

We are honored to be recognized alongside such inspiring organizations and partners. These six finalist nominations reflect the passion, creativity, and expertise of our teams across Inizio. 

Good luck to all of this year’s finalists – we look forward to celebrating the incredible work shaping the future of healthcare marketing. Stay tuned for the results and follow our updates on LinkedIn. 

This content was provided by Inizio

Company Details

- PMLiVE

Inizio

Email
Website

 Latest Content from  Inizio 

Case Study: Understanding the patient journey and addiction treatment pathways

Our client had previously conducted some research and knew that a large proportion of target patients also had addiction issues. They wanted to know more about addiction treatment pathways and...

Research Partnership has published a new Living with Chronic Pain market report for 2016

Chronic pain is defined as pain lasting longer than 6 months and affects 100 million Americans. Living with Chronic Pain is a quantitative study conducted online amongst 390 US patients...

Nutraceuticals: Rich in Potential

Published in eyeforpharma October 2016 by Marc Yates

Case Study: Qualitative research with payers in low and middle income countries

Our client wanted to understand in detail the usage decision drivers, triggers and processes for a high-cost innovative Acute Heart Failure (AHF) drug used in the acute emergency setting in...

Webinar – Immuno-oncology’s Evolution: Implications for Pharma Market Researchers

In association with PMGroup

Case study: Leveraging Market Research Data to Inform Healthcare Providers and the Community

Our client wanted to understand why uptake of HPV vaccination in the Asia-Pacific region was limited.  In order to help increase uptake, they wanted to publish the market research findings...

Towards a culture of evaluation and evidence-based decision making in global health

Reflections on THET Conference 2016: Evidence, Effectiveness & Impact

Research Partnership has published a new Living with Ulcerative Colitis (UC) market report for 2016

Ulcerative Colitis (UC) is a progressive and debilitating disease which affects between 2.5 to 3 million people in Europe. Living with UC is a quantitative study conducted online amongst 325 patients, including...

The Internet of Things

Evolution from man to machine

Therapy Watch expands its oncology portfolio

This month Therapy Watch Oncology will be expanding its portfolio with the addition of Squamous Cell Carcinoma of the Head and Neck (SCCHN). Therapy Watch SCCHN is part of a wider portfolio...